Vivos Inc. (RDGL)
OTCMKTS
· Delayed Price · Currency is USD
0.1194
-0.0036 (-2.91%)
Jun 12, 2025, 3:59 PM EDT
Vivos Employees
Vivos had 1 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$50,243
Profits / Employee
-$3,186,605
Market Cap
54.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Elite Pharmaceuticals | 64 |
| Tian'an Technology Group | 8 |
| CytoDyn | 9 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Vivos News
- 4 weeks ago - Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™ - GlobeNewsWire
- 7 weeks ago - Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025 - GlobeNewsWire
- 2 months ago - Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 6 months ago - Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide - GlobeNewsWire
- 6 months ago - Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial - GlobeNewsWire
- 8 months ago - Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM - GlobeNewsWire
- 11 months ago - Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA - GlobeNewsWire
- 1 year ago - Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials - GlobeNewsWire